Strategies like increasing dietary fiber (which can reduce uremic toxin production by altering microbial fermentation), using pre/probiotics, or novel adsorbents might complement standard renin–angiotensin blockers and SGLT2/GLP-1 therapies in the future management of DKD. This evidence concerns the gene GCG and diabetic kidney disease.